The pharmaceutical industry is experiencing a record-breaking M&A wave in 2026, driven by looming patent cliffs worth $300 billion in annual revenue, FDA regulatory improvements for rare diseases, and the need to diversify portfolios. Companies are making strategic bolt-on acquisitions of late-stage drug candidates rather than massive mergers. While some firms like Eli Lilly are well-positioned, others like Merck and Pfizer face near-term patent expirations that could impact revenue significantly.

Ascendis Pharma reported positive five-year results from its PaTH Forward trial for TransCon PTH (YORVIPATH), showing sustained efficacy and safety in treating adult hypoparathyroidism. The therapy demonstrated that 82% of patients met composite response endpoints, with 88% maintaining normal calcium levels and 96% achieving independence from active vitamin D therapy. The drug showed durable kidney benefits and a consistent safety profile with no new safety signals. ASND stock rose 3.60% to $223.37 on the news.

Ascendis Pharma announced it will present clinical trial data from its rare endocrinology programs at ENDO 2026, including two oral presentations and three posters covering hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency. The presentations will showcase long-term safety and efficacy data for TransCon PTH and benefits of TransCon CNP alone and combined with TransCon hGH in children with achondroplasia.

Ascendis Pharma A/S announced plans to list its ordinary shares directly on Nasdaq effective April 20, 2026, with all outstanding American Depositary Shares (ADSs) to be exchanged on a 1:1 basis for ordinary shares. The company believes the direct listing will broaden global investment access, potentially facilitate inclusion in equity indexes, and enhance institutional ownership and trading liquidity.

The FDA has granted accelerated approval to YUVIWEL (navepegritide), developed by Ascendis Pharma, as the first and only once-weekly treatment for children aged 2 and older with achondroplasia. The drug provides continuous systemic exposure to CNP over the weekly dosing interval and is expected to be commercially available in early Q2 2026. The approval was based on improved annualized growth velocity data from three randomized clinical trials.

BridgeBio Pharma announced positive Phase 3 trial results for infigratinib in treating achondroplasia (dwarfism) in children, showing superior annualized height velocity compared to placebo. The company plans to submit FDA and regulatory applications in the second half of 2026. The stock surged 6.92% to $78.41, nearing its 52-week high.

Ascendis Pharma announced strong 2025 financial results with YORVIPATH generating €477 million and SKYTROFA generating €206 million in revenue. The company expects TransCon CNP approval in the U.S. by February 2026 and outlined expansion plans across multiple product candidates and geographic markets. Strategic collaborations with Novo Nordisk, Eyconis, VISEN Pharmaceuticals, and Teijin Limited are advancing, with a planned $120 million share repurchase program for 2026.

Ascendis Pharma received notification from the FDA extending the PDUFA target action date for TransCon CNP by three months to February 28, 2026, after submitting additional information for their New Drug Application for treating children with achondroplasia.

BioMarin Pharmaceutical reported strong Q4 earnings, beating consensus estimates for both EPS and revenue. The company provided upbeat 2025 guidance, expecting sales of $3.1-$3.2 billion and EPS of $4.20-$4.40.

Ascendis Pharma granted Novo Nordisk an exclusive global license to develop, manufacture, and commercialize Novo Nordisk's proprietary products for metabolic and cardiovascular diseases using Ascendis' TransCon technology platform. The deal includes upfront, milestone, and sales-based payments for Ascendis.

BioMarin reaffirms its $4 billion revenue target for 2027 despite competition from Ascendis Pharma's recent trial data. The company is implementing a $500 million cost transformation program and expects to reach adjusted operating margins of 40% by 2026. Goldman Sachs analyst remains bullish on BioMarin's growth prospects.

Bausch & Lomb and Edgewise Therapeutics were among the top 7 mid-cap stock gainers last week, with Edgewise Therapeutics shares rocketing 50.19% after announcing positive topline data from a clinical trial, and Bausch & Lomb's parent company Bausch Health considering a sale.